Anakinra in the treatment of acute calcium pyrophosphate arthritis

Completed

• Conditions: Chondrocalcinosis; Musculoskeletal Diseases; Other chondrocalcinosis

• Registration Number: ISRCTN46471047
• Lead Sponsor: niversity Hospital Centre and University of Lausanne (CHUV) (Switzerland)-Service of Rheumatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-03-18
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

1. Informed consent
2. Male or female from 18-99 years of age
3. Diagnosis of acute calcium pyrophosphate arthritis based on symptoms of acute arthritis and presence of crystals of chronic calcium pyrophosphate dihydrate (CPPD) in the synovial liquid at screening or from a prior analysis
4. The start of the acute arthritis should be less than 5 days from inclusion in the study

Exclusion Criteria

1. Corticotherapy orally with dose equivalent of prednisone > 10mg during the 24 h preceding inclusion
2. Corticotherapy intramuscular (im) or intravenous (iv) during the 72h preceding inclusion, no matter the dose
3. Corticotherapy intra-articularly during 7 days preceding inclusion
4. Chronic oral corticotherapy of > 10mg daily
5. Uncontrolled respiratory or cardiac failure
6. Other causes of acute arthritis
7. Active gastric or duodenal ulceration
8. Untreated and active malignancy
9. Known intolerance or allergy to the study medications
10. Active and untreated infection assessed by investigator as a contraindication to study medications
11. Other medical problems that are judged prejudicial to the inclusion of the patient in the study by the investigator
12. Pregancy or active breast feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified